Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo - 12/10/12
, Madeleine Duvic, MD b, Ann Martin, MD c, Wolfram Sterry, MD d, Chalid Assaf, MD d, e, David J. Straus, MD f
Reprint requests: H. Miles Prince, MD, Haematology Service, Peter MacCallum Cancer Center, Locked Bag 1, A’Beckett St, Melbourne, Victoria, 8006, Australia.Abstract |
Background |
Spontaneous remission is recognized in mycosis fungoides (MF) and Sézary syndrome (SS).
Objective |
We analyzed the outcome of 44 patients with previously treated CD25-positive (CD25+), recurrent/persistent MF/SS randomly assigned to receive placebo as part of a phase III trial.
Methods |
This trial investigated the efficacy and safety of two doses of denileukin diftitox in patients with MF/SS who had received up to 3 prior therapies. The primary end point was overall response rate. Multivariate regression analyses were used to assess the relationship between baseline covariates and clinical outcomes.
Results |
The overall response rate was 15.9% for placebo recipients (complete response: 2.3%; partial response: 13.6%), reflecting the baseline rate of disease remission that can be expected in a clinical trial. The median progression-free survival (PFS) in the placebo arm was moderately short at 4.4 months compared with the active-agent arm but important to consider in the context of recent single-arm phase II studies of other therapies for MF/SS that report PFS of approximately 6 months. Multivariate analyses identified no significant effects of any baseline factors on either overall response rate or PFS, although there was a trend toward poorer PFS with advanced age. Because sepsis occurred significantly more often in the placebo arm versus the active-treatment arm, the role of antibiotics in causing remission cannot be discounted (6.8% vs 0%; P < .05).
Limitations |
This study had a relatively small sample size, yielding a wide 95% confidence interval.
Conclusion |
The results may serve as a useful comparator for other active-treatment studies of MF/SS that lack a placebo-control arm.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous T-cell lymphoma, denileukin diftitox, lymphoma, mycosis fungoides, placebo, Sézary syndrome, spontaneous remission
Abbreviations used : AE, CCR, CR, CTCL, DD, MF, ORR, PD, PFS, SS
Plan
| Supported by Eisai Inc, Woodcliff Lake, NJ. |
|
| Disclosure: Dr Prince has received honoraria from Eisai Inc for advisory board participation and as a speaker, as well as financial grants for being an investigator. Dr Duvic has received honoraria from Eisai Inc for advisory board participation, as a speaker, and as a consultant, as well as financial grants for being an investigator. Dr Martin has received residency or fellowship program funding from Abbott Laboratories, Maruho Co, and Eisai Inc as an investigator. Dr Assaf had received honoraria from Eisai Inc, Cephalon, and Merck for advisory board participation, and from Eisai Inc and Cephalon as a speaker. Dr Straus has received honoraria from Eisai Inc as an investigator and for advisory board participation. Dr Sterry has no conflicts of interest to declare. |
Vol 67 - N° 5
P. 867-875 - novembre 2012 Retour au numéro
Article précédent
- Multidisciplinary approach to the management of dermatofibrosarcoma protuberans
- Donald W. Buck, John Y.S. Kim, Murad Alam, Vinay Rawlani, Sarah Johnson, Caitlin M. Connor, Gregory A. Dumanian, Jeffrey D. Wayne
- Sunscreen use and availability among female collegiate athletes
- Lauren E. Dubas, Brian B. Adams
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?